Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

High‐throughput automated scoring of Ki67 in breast cancer tissue microarrays from the Breast Cancer Association Consortium
Howat, William , Daley, Frances , Zabaglo, Lila, McDuffus, Leigh‐Anne, Blows, Fiona M., Coulson, Penny , Ali, H. Raza , Benı́tez, Javier , Brenner, Hermann , Stegmaier, Christa, Mannermaa, Arto, Chang‐Claude, Jenny , Sinn, Hans‐Peter , Tollenaar, Rob A.�E.�M. , Devilee, Peter , Figueroa, Jonine D. , Sherman, Mark E., Lissowska, Jolanta , Hewitt, Stephen M. , Eccles, Diana , Hooning, Maartje J. , Deurzen, Carolien HM van, Investigators, kConFab, Bolla, Manjeet K. , Wang, Qin , Jones, Michael E. , Schoemaker, Minouk J. , Leeuwen, Flora E. van , Veer, Laura van’t, Swerdlow, Anthony J. , Orr, Nick , Dowsett, Mitch , Easton, Douglas F. , Schmidt, Marjanka K. , García‐Closas, Montserrat , Abubakar, Mustapha , Milne, Roger L. , Mannermaa, Arto, Rudolph, Anja , Couch, Fergus J. , Hollestelle, Antoinette , Martens, John W.M. , Deurzen, Carolien HM van, Broeks, Annegien , Pharoah, Paul D.P. , Eccles, Diana , Swerdlow, Anthony J , Lissowska, Jolanta , Sinn, Peter , Jones, Michael E , Brenner, Hermann , García-Closas, Montserrat , Schmidt, Marjanka K , Benitez, Javier , Figueroa, Jonine D , Devilee, Peter , Schoemaker, Minouk J , Orr, Nick

Mayo Clinic

The Journal of Pathology: Clinical Research | March 2, 2016 | Volume: 2 | Issue: 3 | Pages: 138-153

10.1002/cjp2.42 | PMID 27499923 Get It

AbstractAutomated methods are needed to facilitate high‐throughput and reproducible scoring of Ki67 and other markers in breast cancer tissue microarrays (TMAs) in large‐scale studies. To address this need, we developed an automated protocol for Ki67 scoring and evaluated its performance in studies from the Breast Cancer Association Consortium. We utilized 166 TMAs containing 16,953 tumour cores representing 9,059 breast cancer cases, from 13 studies, with information on other clinical and pathological characteristics. TMAs were stained for Ki67 using standard immunohistochemical procedures, and scanned and digitized using the Ariol system. An automated algorithm was developed for the scoring of Ki67, and scores were compared to computer assisted visual (CAV) scores in a subset of 15 TMAs in a training set. We also assessed the correlation between automated Ki67 scores and other clinical and pathological characteristics. Overall, we observed good discriminatory accuracy (AUC = 85%) and good agreement (kappa = 0.64) between the automated and CAV scoring methods in the training set. The performance of the automated method varied by TMA (kappa range= 0.37–0.87) and study (kappa range = 0.39–0.69). The automated method performed better in satisfactory cores (kappa = 0.68) than suboptimal (kappa = 0.51) cores (p‐value for comparison = 0.005); and among cores with higher total nuclei counted by the machine (4,000–4,500 cells: kappa = 0.78) than those with lower counts (50–500 cells: kappa = 0.41; p‐value = 0.010). Among the 9,059 cases in this study, the correlations between automated Ki67 and clinical and pathological characteristics were found to be in the expected directions. Our findings indicate that automated scoring of Ki67 can be an efficient method to obtain good quality data across large numbers of TMAs from multicentre studies. However, robust algorithm development and rigorous pre‐ and post‐analytical quality control procedures are necessary in order to ensure satisfactory performance.
Predicting Barrett's Esophagus in Families: An Esophagus Translational Research Network (BETRNet) Model Fitting Clinical Data to a Familial Paradigm
Sun, Xiangqing , Elston, Robert C. , Barnholtz‐Sloan, Jill S. , Faulx, Ashley L., Mittal, Sumeet K. , Shaheen, Nicholas J. , Wang, Jean S. , Iyer, Prasad G. , Tian, Ye D. , Willis, Joseph , Guda, Kishore , Markowitz, Sanford D. , Chandar, Apoorva K., Warfe, James M. , Brock, Wendy , Chak, Amitabh , Falk, Gary W. , Grady, William M. , Canto, Marcia Irene , Abrams, Julian A , Willis, Joseph E , Barnholtz-Sloan, Jill S

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | February 29, 2016 | Volume: 25 | Issue: 5 | Pages: 727-735

10.1158/1055-9965.epi-15-0832 | PMID 26929243 Get It

Abstract Background: Barrett's esophagus is often asymptomatic and only a small portion of Barrett's esophagus patients are currently diagnosed and under surveillance. Therefore, it is important to develop risk prediction models to identify high-risk individuals with Barrett's esophagus. Familial aggregation of Barrett's esophagus and esophageal adenocarcinoma, and the increased risk of esophageal adenocarcinoma for individuals with a family history, raise the necessity of including genetic factors in the prediction model. Methods to determine risk prediction models using both risk covariates and ascertained family data are not well developed. Methods: We developed a Barrett's Esophagus Translational Research Network (BETRNet) risk prediction model from 787 singly ascertained Barrett's esophagus pedigrees and 92 multiplex Barrett's esophagus pedigrees, fitting a multivariate logistic model that incorporates family history and clinical risk factors. The eight risk factors, age, sex, education level, parental status, smoking, heartburn frequency, regurgitation frequency, and use of acid suppressant, were included in the model. The prediction accuracy was evaluated on the training dataset and an independent validation dataset of 643 multiplex Barrett's esophagus pedigrees. Results: Our results indicate family information helps to predict Barrett's esophagus risk, and predicting in families improves both prediction calibration and discrimination accuracy. Conclusions: Our model can predict Barrett's esophagus risk for anyone with family members known to have, or not have, had Barrett's esophagus. It can predict risk for unrelated individuals without knowing any relatives' information. Impact: Our prediction model will shed light on effectively identifying high-risk individuals for Barrett's esophagus screening and surveillance, consequently allowing intervention at an early stage, and reducing mortality from esophageal adenocarcinoma. Cancer Epidemiol Biomarkers Prev; 25(5); 727–35. ©2016 AACR.
Foxa1 is essential for mammary duct formation
Zhao, Yongbing , Skerry, Benjamin, Wang, Xiao , Colin, Christelle , Li, Zhaoyu , Colin-Cassin, Christelle, Radisky, Derek C. , Liu, Yi , Kaestner, Klaus H. , Li, Zhaoyu

Mayo Clinic

genesis | February 26, 2016 | Volume: 54 | Issue: 5 | Pages: 277-285

10.1002/dvg.22929 | PMID 26919034 Get It

Summary The transcription factor forkhead box protein A1 (FOXA1) plays a critical role in the proliferation of human breast cancer cells, particularly estrogen receptor alpha (ERα)‐positive luminal breast cancer cells. However, genetic studies of the requirement for Foxa1 in mammary tumor formation in mice have been hampered by the lack of a conditional gene ablation. We examined three mouse models of mammary‐specific ablation of Foxa1 in ductal epithelial cells to identify the best system for complete and mammary‐specific ablation of Foxa1. We found that MMTV‐Cre and MMTV‐rtTA;Tet‐On‐Cre led to partial deletion of Foxa1 and attenuated mammary duct formation, whereas Krt14‐Cre led to complete ablation of Foxa1 and abolished mammary duct formation, in Foxa1 loxP/loxP mice. These results demonstrate that Foxa1 is essential for mammary duct formation, and reveal a series of mouse models in which mammary expression of Foxa1 can be attenuated or completely blocked. Our study also suggests a potentially powerful model for complete ablation of Foxa1 in mammary epithelial cells using Krt14‐driven Cre expression in an inducible manner, such as Krt14‐rtTA;Tet‐On‐Cre . This model system will facilitate further in vivo functional studies of Foxa1 or other factors in mammary gland development and tumor formation and progression. genesis 54:277–285, 2016. © 2016 Wiley Periodicals, Inc.
P300 acetyltransferase regulates fatty acid synthase expression, lipid metabolism and prostate cancer growth
Gang, Xiaokun , Yang, Yinhui , Zhong, Jian , Jiang, Kui , Pan, Yunqian , Karnes, R. Jeffrey , Xu, Wanhai , Wang, Guixia , Gang, Xiaokun , Zhang, Jun , Huang, Haojie

Mayo Clinic

Oncotarget | February 25, 2016 | Volume: 7 | Issue: 12 | Pages: 15135-15149

10.18632/oncotarget.7715 | PMID 26934656 Get It

RNA‐seq analysis of clinical‐grade osteochondral allografts reveals activation of early response genes
Yang, Lin , Lewallen, Eric A. , Camilleri, Emily T. , Bonin, Carolina A. , Jones, Dakota L. , Dudakovic, Amel , Galeano‐Garces, Catalina , Wang, Wei , Karperien, Marcel , Larson, A. Noelle , Dahm, Diane L., Levy, Bruce A. , Smith, Jay , Ryssman, Daniel B., Im, Hee‐Jeong , Wijnen, André J. van , Riester, Scott M. , Krych, Aaron J. , Camilleri, Emily , Lin, Yang , Larson, Annalise N, van Wijnen, Andre J, Stuart, Michael J. , Westendorf, Jennifer J. , van Wijnen, Andre J , Krych, Aaron J , Larson, A Noelle , Camilleri, Emily

Mayo Clinic

Journal of Orthopaedic Research | February 25, 2016 | Volume: 34 | Issue: 11 | Pages: 1950-1959

10.1002/jor.23209 | PMID 26909883 Get It

ABSTRACTPreservation of osteochondral allografts used for transplantation is critical to ensure favorable outcomes for patients after surgical treatment of cartilage defects. To study the biological effects of protocols currently used for cartilage storage, we investigated differences in gene expression between stored allograft cartilage and fresh cartilage from living donors using high throughput molecular screening strategies. We applied next generation RNA sequencing (RNA‐seq) and real‐time reverse transcription quantitative polymerase chain reaction (RT‐qPCR) to assess genome‐wide differences in mRNA expression between stored allograft cartilage and fresh cartilage tissue from living donors. Gene ontology analysis was used to characterize biological pathways associated with differentially expressed genes. Our studies establish reduced levels of mRNAs encoding cartilage related extracellular matrix (ECM) proteins (i.e., COL1A1, COL2A1, COL10A1, ACAN, DCN, HAPLN1, TNC, and COMP) in stored cartilage. These changes occur concomitantly with increased expression of “early response genes” that encode transcription factors mediating stress/cytoprotective responses (i.e., EGR1, EGR2, EGR3, MYC, FOS, FOSB, FOSL1, FOSL2, JUN, JUNB, and JUND). The elevated expression of “early response genes” and reduced levels of ECM‐related mRNAs in stored cartilage allografts suggests that tissue viability may be maintained by a cytoprotective program that reduces cell metabolic activity. These findings have potential implications for future studies focused on quality assessment and clinical optimization of osteochondral allografts used for cartilage transplantation. © 2016 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 34:1950–1959, 2016.
Cardiac troponin in patients hospitalized with acute decompensated heart failure: A systematic review and meta‐analysis
Yousufuddin, Mohammed , Abdalrhim, Ahmed D., Murad, M. Hassan , Wang, Zhen , Murad, M Hassan

Mayo Clinic

Journal of Hospital Medicine | February 18, 2016 | Volume: 11 | Issue: 6 | Pages: 446-454

10.1002/jhm.2558 | PMID 26889916 Get It

BACKGROUNDElevated cardiac troponin (cTn) is often observed in patients with acute decompensated heart failure (ADHF). We assessed the magnitude of association and quality of supporting evidence between cTn and clinically important outcomes in persons hospitalized for ADHF.METHODSWe searched MEDLINE In‐Process & Other Non‐Indexed Citations, MEDLINE, Embase, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Scopus from inception through February 28, 2015. The outcomes analyzed included hospital length of stay (LOS), readmissions, and mortality. Random effects meta‐analysis was used to combine outcomes across studies.RESULTSWe included 26 clinical studies. A detectable or elevated cTn was associated with increased LOS (odds ratio [OR]: 1.05; 95% confidence interval [CI]: 1.01‐1.10), increased in‐hospital mortality (OR: 2.57; 95% CI: 2.27‐2.91), and a composite of mortality and major adverse events (OR: 1.33; 95% CI: 1.03‐1.71) during hospitalization. ADHF patients with a detectable or elevated cTn were at increased risk for mortality and composite of mortality and readmission over the short term (mortality OR: 2.11; 95% CI: 1.43‐3.12; composite OR: 2.81; 95% CI: 1.60‐4.92), intermediate term (mortality OR: 2.21; 95% CI: 1.46‐3.35; composite OR: 2.30; 95% CI: 1.78‐2.99), and long term (mortality OR: 3.69; 95% CI: 2.64‐5.18; composite OR: 3.49; 95% CI: 2.08‐5.84). The overall confidence in estimates was moderate.CONCLUSIONSAmong ADHF patients, a detectable or elevated cTn identifies subjects at increased risk for adverse clinical outcomes during acute hospitalization and those at higher risk for postdischarge mortality and composite of readmission and mortality. Journal of Hospital Medicine 2016;11:446–454. 2016 Society of Hospital Medicine
Estrogen, SNP-Dependent Chemokine Expression and Selective Estrogen Receptor Modulator Regulation
Ho, Ming‐Fen , Bongartz, Tim, Liu, Mohan , Kalari, Krishna R. , Goss, Paul E. , Shepherd, Lois E. , Kubo, Michiaki , Wang, Liewei , Weinshilboum, Richard M. , Ingle, James N. , Goetz, Matthew P. , Weinshilboum, Richard M. , Kalari, Krishna R , Ho, Ming-Fen

Mayo Clinic

Molecular Endocrinology | February 11, 2016 | Volume: 30 | Issue: 3 | Pages: 382-398

10.1210/me.2015-1267 | PMID 26866883 Get It

Abstract We previously reported, on the basis of a genome-wide association study for aromatase inhibitor-induced musculoskeletal symptoms, that single-nucleotide polymorphisms (SNPs) near the T-cell leukemia/lymphoma 1A (TCL1A) gene were associated with aromatase inhibitor-induced musculoskeletal pain and with estradiol (E2)-induced TCL1A expression. Furthermore, variation in TCL1A expression influenced the downstream expression of proinflammatory cytokines and cytokine receptors. Specifically, the top hit genome-wide association study SNP, rs11849538, created a functional estrogen response element (ERE) that displayed estrogen receptor (ER) binding and increased E2 induction of TCL1A expression only for the variant SNP genotype. In the present study, we pursued mechanisms underlying the E2-SNP-dependent regulation of TCL1A expression and, in parallel, our subsequent observations that SNPs at a distance from EREs can regulate ERα binding and that ER antagonists can reverse phenotypes associated with those SNPs. Specifically, we performed a series of functional genomic studies using a large panel of lymphoblastoid cell lines with dense genomic data that demonstrated that TCL1A SNPs at a distance from EREs can modulate ERα binding and expression of TCL1A as well as the expression of downstream immune mediators. Furthermore, 4-hydroxytamoxifen or fulvestrant could reverse these SNP-genotype effects. Similar results were found for SNPs in the IL17A cytokine and CCR6 chemokine receptor genes. These observations greatly expand our previous results and support the existence of a novel molecular mechanism that contributes to the complex interplay between estrogens and immune systems. They also raise the possibility of the pharmacological manipulation of the expression of proinflammatory cytokines and chemokines in a SNP genotype-dependent fashion.
A critical role for alternative polyadenylation factor CPSF6 in targeting HIV-1 integration to transcriptionally active chromatin
Sowd, Gregory A. , Serrao, Erik , Wang, Hao , Fadel, Hind J., Poeschla, Eric M. , Engelman, Alan , Wang, Weifeng

Mayo Clinic

Proceedings of the National Academy of Sciences | February 9, 2016 | Volume: 113 | Issue: 8 | Pages: No page available

10.1073/pnas.1524213113 | PMID 26858452 Get It

Significance HIV-1 requires integration for efficient gene expression, and the local chromatin environment significantly influences the level of HIV-1 transcription. Silent, integrated proviruses constitute the latent HIV reservoir. As HIV-1 commandeers cellular factors to dictate its preferred integration sites, these interactions consequentially influence latency. We examined the impact of polyadenylation specificity factor CPSF6, which binds HIV-1 capsid, and the integrase-binding chromatin reader LEDGF/p75 on viral infection and integration site distribution. Integration sites were determined in cells knocked down or knocked out for one or both host factors. Our data indicate that CPSF6 directs HIV-1 to transcriptionally active chromatin, where LEDGF/p75 predominantly directs the positions of integration within genes. These findings clarify the roles of cellular forces that dictate HIV-1 integration preferences and hence virus pathogenesis.
A Novel Selectable Islet 1 Positive Progenitor Cell Reprogrammed to Expandable and Functional Smooth Muscle Cells
Turner, Elizabeth C., Huang, Chien‐Ling , Sawhney, Neha, Govindarajan, Kalaimathi, Clover, Anthony J. P., Martin, Kenneth, Browne, Tara C., Whelan, Derek , Kumar, Arun , Mackrill, John J. , Wang, Shaohua , Schmeckpeper, Jeffrey , Stocca, Alessia, Pierce, William Gamewell, Leblond, Anne‐Laure , Cai, Liquan , O’Sullivan, Donnchadh , Büneker, Chirlei Klein, Choi, Janet , MacSharry, John , Russell, Stephen J. , Caplice, Noel M. , Ikeda, Yasuhiro , Russell, Stephen J

Mayo Clinic

Stem Cells | February 3, 2016 | Volume: 34 | Issue: 5 | Pages: 1354-1368

10.1002/stem.2319 | PMID 26840832 Get It

AbstractDisorders affecting smooth muscle structure/function may require technologies that can generate large scale, differentiated and contractile smooth muscle cells (SMC) suitable for cell therapy. To date no clonal precursor population that provides large numbers of differentiated SMC in culture has been identified in a rodent. Identification of such cells may also enhance insight into progenitor cell fate decisions and the relationship between smooth muscle precursors and disease states that implicate differentiated SMC. In this study, we used classic clonal expansion techniques to identify novel self-renewing Islet 1 (Isl-1) positive primitive progenitor cells (PPC) within rat bone marrow that exhibited canonical stem cell markers and preferential differentiation towards a smooth muscle-like fate. We subsequently used molecular tagging to select Isl-1 positive clonal populations from expanded and de novo marrow cell populations. We refer to these previously undescribed cells as the PPC given its stem cell marker profile, and robust self-renewal capacity. PPC could be directly converted into induced smooth muscle cells (iSMC) using single transcription factor (Kruppel-like factor 4) knockdown or transactivator (myocardin) overexpression in contrast to three control cells (HEK 293, endothelial cells and mesenchymal stem cells) where such induction was not possible. iSMC exhibited immuno- and cytoskeletal-phenotype, calcium signaling profile and contractile responses similar to bona fide SMC. Passaged iSMC could be expanded to a scale sufficient for large scale tissue replacement. PPC and reprogramed iSMC so derived may offer future opportunities to investigate molecular, structure/function and cell-based replacement therapy approaches to diverse cardiovascular, respiratory, gastrointestinal, and genitourinary diseases that have as their basis smooth muscle cell functional aberrancy or numerical loss.